HALO vs. TAK: Halozyme Therapeutics vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Halozyme Therapeutics (HALO) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Halozyme Therapeutics (HALO) has a non-negative beta of 0.96.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Takeda Pharmaceutical (TAK) at 0.56%, which is closer to a typical peer reading.

Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both Halozyme Therapeutics (HALO) at 59.84% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Halozyme Therapeutics (HALO) at 37.55% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Halozyme Therapeutics (HALO) at -25.36% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

Only one side’s leverage can be read here: Takeda Pharmaceutical (TAK) carries debt-to-equity ratio of 0.72 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Takeda Pharmaceutical (TAK) reports 1.43, ranking against industry peers normally.

Valuation Metrics